Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Psychiatric services (Washington, D.C.) - 1 Nov 2009

Laje Gonzalo, Perlis Roy H, Rush A John, McMahon Francis J

Abstract excerpt

Several lines of evidence support an important genetic contribution to the wide individual variation in therapeutic response to antidepressant medications. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study provided the largest cohort assembled to date of DNA from patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Citalopram
Share to Cognitive Behavioral Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclohexanols

Share to Dopamine Uptake Inhibitors

Share to Receptors, Kainic Acid

Share to Serotonin Receptor Agonists

Share to Venlafaxine Hydrochloride

Source

Open in PubMed Open full text

Identifiers

PMID: 19880459
DOI: 10.1176/appi.ps.60.11.1446
PMCID: PMC3775610

Genes

GRIA3
GRIK2
BDNF
FKBP5
GRIA1
GRIK4
KCNK2
PAPLN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19880459-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.PMID 19880459Read ↗

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.Semantic proximity Read ↗

Pharmacogenomics with antidepressants in the STAR*D study.Semantic proximity Read ↗

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.Semantic proximity Read ↗

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Semantic proximity Read ↗

Antidepressant pharmacogeneticsSemantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

Genome-wide association studies of antidepressant outcome: a brief review.Semantic proximity Read ↗

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.Semantic proximity Read ↗

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients.Semantic proximity Read ↗

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis.Semantic proximity Read ↗

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read ↗

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.